Abstract:Objective:To explore the efficacy and safety of patent ductus arteriosus (PDA) ligation in extremely premature infants.Methods:Clinical data were retrospectively reviewed for 49 extremely preterm PDA infants admitted into Neonatal Intensive Care Unit of Children's Hospital, Zhejiang University School of Medicine. They underwent surgical intervention at Department of Cardiac Surgery from January 2015 to December 2019. There were 27 boys and 22 girls with a gestational age < 28 weeks, an average gestational age of 26 +5 weeks and a gestational age range of 24 +5 to 27 +6 weeks; multiple pregnancies accounted for 38.8% (19/49) ; birth weight was (930±148) g; diameter of PDA assessed by preoperative ultrasound was (4.0±0.8) mm; there were approximately 1.6 courses of drug treatment. Basic clinical data, early surgical prognosis, inhospital mortality and operation-related complications were recorded. Durations of ventilator support and oxygen therapy before and after operation were compared. And clinical characteristics and therapeutic effect of PDA ligation were summarized. Results:Operative duration was (52±16) min, average operative age 42.4 days, average operative weight 1.68 kg, median diameter of PDA 3.8 mm, average corrected age at discharge 42 +6 weeks and average weight at discharge 3.47 kg. Without mortality, none had residual fistula postoperatively and achieved immediate closure. Two children had left vocal cord paralysis preoperatively. No new case of nerve injury occurred postoperatively. Postoperative pneumothorax accounted for 10.2% (5/49) . Four pre-discharge deaths were not related with surgery and there was an in-hospital mortality rate of 8.2 % (4/49 ) . Preoperative invasive mechanical ventilation support accounted for 85.7% (42/49) and non-invasive positive pressure ventilation support 14.3% (7/49) . Total mechanical ventilation time during hospitalization was (42±37) days and total ventilator support time of invasive mechanical ventilation and non-invasive positive pressure ventilation was (73±34) days. The differences between pre and post-operation of invasive mechanical ventilation time and total ventilator support time were (12.4±26.5) and (32.2±35.0) days ( P=0.003, P<0.001) and the differences were statistically significant. Survival analysis revealed that infants with multiple pregnancies, operative weight ≥1.5 kg and PDA diameter < 3.8 mm could be weaned off ventilator treatment and oxygen therapy earlier postoperatively. Conclusions:Surgical ligation is both safe and effective for PDA in extremely premature infants.

Effect of prostaglandin-E1 treatment on pyloric wall thickness in newborns with ductal-dependent critical congenital heart diseases

Prostaglandin E1 used as a pre-operative treatment for the neonates with transposition of great vessels with intact ventricular septum

Long-Term Prostaglandin E1 Infusion for Newborns with Critical Congenital Heart Disease

Prolonged prostaglandin E1 therapy in a neonate with pulmonary atresia and ventricular septal defect and the development of antral foveolar hyperplasia and hypertrophic pyloric stenosis

Long Term Prostaglandin-E Therapy in Neonates with Emphasis on Complications in the Long Bones

Treatment of Patent Ductus Arteriosus and Short-Term Outcomes among Extremely Preterm Infants: a Multicentre Cohort Study

Reappraisal of the Prostaglandin E1 Dose for Early Newborns with Patent Ductus Arteriosus-Dependent Pulmonary Circulation

Prostaglandin‐E1 infusion in persistent pulmonary hypertension of the newborn

Analysis of the effect of ligation of ductus arteriosus in premature infants

Prostaglandin E1-induced urticaria with harlequin change in a neonate with transposition of great vessels: A case report

Low-dose prostaglandin E1 is safe and effective for critical congenital heart disease: is it time to revisit the dosing guidelines?

Effect of Long-term Administration of Prostaglandin E1 on Morphologic Changes in Ductus Arteriosus

Effects of Prostaglandin E1 and Balloon Atrial Septostomy on Cerebral Blood Flow and Oxygenation in Newborns Diagnosed with Transposition of the Great Arteries

Effects of Prostaglandin E_1 on Hyperoxia Induced Lung Injury in Neonatal Rats

The impact of cyclooxygenase inhibitor use on urinary prostaglandin metabolites in preterm infants

Do Predictors Exist for a Successful Withdrawal of Preoperative Prostaglandin E1 from Neonates with d-Transposition of the Great Arteries and Intact Ventricular Septum?

Association Between Early Prostacyclin Therapy and Extracorporeal Life Support Use in Patients With Congenital Diaphragmatic Hernia

Assessment of Blood Prostaglandin E2 Metabolite Levels among Infants Born Preterm with Patent Ductus Arteriosus: A Prospective Study

Efficacy and Safety of Oral Paracetamol vs. Oral Ibuprofen in the Treatment of Symptomatic Patent Ductus Arteriosus in Premature Infants

Effect of Prenatal Tetrandrine Therapy on Pulmonary Vascular Structural Remodeling in the Nitrofen-Induced CDH Rat Model.

1527 PROSTAGLANDIN D2 DOES NOT LOWER PULMONARY ARTERIAL PRESSURE OR IMPROVE OXYGENATION IN INFANTS WITH PERSISTENT PULMONARY HYPERTENSION SYNDROME (PPHN)